HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The PPARγ agonist pioglitazone prevents TGF-β induced renal fibrosis by repressing EGR-1 and STAT3.

AbstractBACKGROUND:
It has been proposed that peroxisome proliferator-activated receptor-γ (PPARγ) agonists might reduce renal fibrosis, however, several studies had contradictory results. Moreover, the possible interaction of TGF-β1, PPARγ, and transcription factors in renal fibrosis have not been investigated. We hypothesized that oral pioglitazone treatment would inhibit TGF-β-driven renal fibrosis and its progression, by modulating profibrotic transcription factors in TGF-β1 transgenic mice.
METHODS:
Male C57Bl/6 J mice (control, CTL, n = 14) and TGF-β overexpressing transgenic mice (TGFβ, n = 14, having elevated plasma TGF-β1 level) were divided in two sets at 10 weeks of age. Mice in the first set were fed with regular rodent chow (CTL and TGFβ, n = 7/group). Mice in the second set were fed with chow containing pioglitazone (at a dose of 20 mg/kg/day, CTL + Pio and TGFβ+Pio, n = 7/group). After 5 weeks of treatment, blood pressure was assessed and urine samples were collected, and the kidneys were analyzed for histology, mRNA and protein expression.
RESULTS:
TGF-β1 induced glomerulosclerosis and tubulointerstitial damage were significantly reduced by pioglitazone. Pioglitazone inhibited renal mRNA expression of all the profibrotic effectors: type-III collagen, TGF-β1, CTGF and TIMP-1, and alike transcription factors cFos/cJun and protein expression of EGR-1, and STAT3 protein phosphorylation.
CONCLUSIONS:
Oral administration of PPARγ agonist pioglitazone significantly reduces TGF-β1-driven renal fibrosis, via the attenuation of EGR-1, STAT3 and AP-1. This implies that PPARγ agonists might be effective in the treatment of chronic kidney disease patients.
AuthorsÁgnes Németh, Miklós M Mózes, Laurent Calvier, Georg Hansmann, Gábor Kökény
JournalBMC nephrology (BMC Nephrol) Vol. 20 Issue 1 Pg. 245 (07 05 2019) ISSN: 1471-2369 [Electronic] England
PMID31277592 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Early Growth Response Protein 1
  • Egr1 protein, mouse
  • PPAR gamma
  • STAT3 Transcription Factor
  • Stat3 protein, mouse
  • Transforming Growth Factor beta
  • Pioglitazone
Topics
  • Animals
  • Early Growth Response Protein 1 (antagonists & inhibitors, metabolism)
  • Fibrosis
  • Kidney Diseases (chemically induced, metabolism, prevention & control)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • PPAR gamma (agonists)
  • Pioglitazone (pharmacology, therapeutic use)
  • STAT3 Transcription Factor (antagonists & inhibitors, metabolism)
  • Transforming Growth Factor beta (antagonists & inhibitors, toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: